开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2022-10-06 slientwo

审稿速度:2.0 | 投稿命中率:25.0
经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。

92 0

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2022-04-01 143050_0848

需要上传原始数据吗

134 0

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2017-02-10 毛大丁

OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高

475 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2021-12-29 学医的彭于晏

什么是三线表？

126 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2021-12-28 rayms

一般期刊要求图表的格式是什么？

143 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2019-03-30 ms4729674192825029

马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊

244 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2020-12-31 lovetcm

EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前

223 0

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2019-04-18 sunliang

钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表:
OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高

毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高

272 0

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2018-02-26 毛大丁

审稿速度:1.0 | 投稿命中率:50.0
经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高

476 0

[GetPortalCommentsPageByObjectIdResponse(id=2092122, encodeId=7b19209212209, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：EMBO出版社的老三，主要关注临床药物开发，稿子不算多，但是质量还是不错的。拒你同样也很快，EMBO旗下杂志，其实真的很好，不会耽误时间，编辑态度有友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Thu Oct 06 19:12:15 CST 2022, time=2022-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207901, encodeId=c12f120e901ba, content=需要上传原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efcf6269379, createdName=143050_0848, createdTime=Fri Apr 01 17:45:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532672, encodeId=10535326e279, content=OPEN ACCESS的文章，版面费巨贵，各种抗体什么的还要给验证数据，反正就是很繁琐。不过IF确实越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=475, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Fri Feb 10 14:30:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103450, encodeId=f19611034503f, content=什么是三线表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103449, encodeId=a9be1103449bd, content=一般期刊要求图表的格式是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=850553, encodeId=952f8505539c, content=马上under editorial consideration，后5天拒稿。但拒稿信很牵强。但可以转投其他embo期刊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2bd5414155, createdName=ms4729674192825029, createdTime=Sat Mar 30 11:20:35 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912781, encodeId=bdd5912e81d9, content=EMBO杂志的分数大概9分多，几个杂志的分数基本稳定， EMBO Molecular Medicine 2020年应该会涨到10分。以前10分的杂志很少，所以EMBO杂志比较有影响力，而现在10分以上杂志越来越多，它的名气不如以前, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Dec 31 22:08:24 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=569693, encodeId=342d56969331, content=钱不是问题，能发就行，单位的奖励也够版面费了。毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=毛大丁 2018-02-26 15:37:00 发表: OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Thu Apr 18 00:00:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553010, encodeId=a90f553010f6, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：OPEN ACCESS的文章，版面费巨贵，3000欧元，各种抗体什么的还要给验证数据，反正就是很繁琐，反过来可以理解为数据可信度高。IF每年都是越来越高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=476, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29702019003, createdName=毛大丁, createdTime=Mon Feb 26 15:37:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549752, encodeId=776c549e525b, content=版面费需要多少啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=535, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74411664721, createdName=geneandu, createdTime=Wed Dec 06 09:38:00 CST 2017, time=2017-12-06, status=1, ipAttribution=)]

2017-12-06 geneandu

版面费需要多少啊？

535 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务